UBS raised the firm’s price target on Edwards Lifesciences (EW) to $92 from $90 and keeps a Neutral rating on the shares following the analyst day. The firm says the company’s long-term guidance could prove conservative.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Cautious Optimism for Edwards Lifesciences: Hold Rating Maintained Amid Back-End-Loaded Growth Expectations
- Edwards Lifesciences price target raised to $88 from $83 at Baird
- Edwards Lifesciences price target raised to $100 from $95 at Stifel
- Edwards Lifesciences price target raised to $89 from $84 at Canaccord
- Edwards Lifesciences price target raised to $96 from $95 at Wells Fargo